Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control

被引:81
|
作者
Ting, F. [1 ,2 ,3 ]
Tran, M. [1 ,2 ,3 ]
Boehm, M. [2 ]
Siriwardana, A. [1 ,2 ,3 ]
Van Leeuwen, P. J. [1 ,2 ]
Haynes, A-M [2 ]
Delprado, W. [4 ]
Shnier, R. [5 ]
Stricker, P. D. [1 ,2 ,3 ]
机构
[1] St Vincents Prostate Canc Ctr, Darlinghurst, NSW, Australia
[2] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia
[3] Univ New S Wales, Sch Med, Sydney, NSW, Australia
[4] Douglass Hanly Moir Pathol, Macquarie Pk, NSW, Australia
[5] Southern Radiol, Randwick, NSW, Australia
基金
英国医学研究理事会;
关键词
ABLATION; THERAPY; METAANALYSIS; TRIAL; MEN;
D O I
10.1038/pcan.2015.47
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Current data on the use of irreversible electroporation (IRE) in the treatment of prostate cancer (PCa) is limited. We aim to evaluate the safety, short-term functional and oncological outcomes of focal IRE in low-intermediate risk PCa. METHODS: Between February 2013 and May 2014, 32 consecutive men underwent IRE at a single centre. Patients with low-intermediate risk PCa who had not received previous PCa treatment were included for analysis. The tumour was ablated using 3-6 electrodes, ensuring a minimum 5-mm safety margin around the visible magnetic resonance imaging (MRI) lesion. Follow-up included recording Clavien complications, Expanded Prostate Cancer Index Composite (EPIC) questionnaires (baseline, 1.5, 3, 6 months), 6-month multi-parametric MRI (mp-MRI) and 7-month biopsy. Findings on mp-MRI and biopsy were sub-divided into infield, adjacent or outfield of the treatment zone. RESULTS: Twenty-five men were included for final analysis. Safety follow-up revealed one Clavien Grade 3 complication and five Grade 1 complications. Functional follow-up confirmed no significant change in American Urological Association urinary symptom score, sexual or bowel function. Infield, there were no suspicious findings on mp-MRI (n = 24) or biopsy (n = 21) in all patients. Adjacent to the treatment zone, five (21%) had suspicious findings on mp-MRI with four (19%) proving to be significant on biopsy. Outfield, there were two (8%) with suspicious findings on mp-MRI and one (5%) significant finding on biopsy. For the five patients with significant findings on follow-up biopsy, one is awaiting repeat IRE, one had radical prostatectomy and three remained on active surveillance. CONCLUSIONS: In selected patients with low-intermediate risk PCa, focal IRE appears to be safe with minimal morbidity. There were no infield recurrences and 76% of patients were histologically free of significant cancer at 8 months. Almost all recurrences were adjacent to the treatment zone, and this was addressed by widening the treatment margins.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [31] Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE)
    Alexandar Blazevski
    Amer Amin
    Matthijs J. Scheltema
    Anjali Balakrishnan
    Anne-Maree Haynes
    Daniela Barreto
    Thomas Cusick
    James Thompson
    Phillip D. Stricker
    World Journal of Urology, 2021, 39 : 1107 - 1114
  • [32] Irreversible electroporation. Current value for focal treatment of prostate cancer
    Wendler, J. J.
    Ganzer, R.
    Hadaschik, B.
    Blana, A.
    Henkel, T.
    Koehrmann, K. U.
    Machtens, S.
    Roosen, A.
    Salomon, G.
    Sentker, L.
    Witzsch, U.
    Schlemmer, H. P.
    Baumunk, D.
    Koellermann, J.
    Schostak, M.
    Liehr, U. B.
    UROLOGE, 2015, 54 (06): : 854 - 862
  • [33] Prostate Cancer Recurrence and Persistence After Irreversible Electroporation Focal Ablation
    Isharwal, Sumit
    Greene, Kirsten L.
    JAMA SURGERY, 2023, 158 (04) : 349 - 349
  • [34] Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE)
    Blazevski, Alexandar
    Amin, Amer
    Scheltema, Matthijs J.
    Balakrishnan, Anjali
    Haynes, Anne-Maree
    Barreto, Daniela
    Cusick, Thomas
    Thompson, James
    Stricker, Phillip D.
    WORLD JOURNAL OF UROLOGY, 2021, 39 (04) : 1107 - 1114
  • [35] Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort
    Blazevski, Alexandar
    Scheltema, Matthijs J.
    Yuen, Brian
    Masand, Natasha
    Nguyen, Tuan, V
    Delprado, Warick
    Shnier, Ron
    Haynes, Anne-Maree
    Cusick, Thomas
    Thompson, James
    Stricker, Phillip
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (03): : 283 - 290
  • [36] Irreversible Electroporation for Prostate Cancer
    Ong, Sean
    Leonardo, Matthew
    Chengodu, Thilakavathi
    Bagguley, Dominic
    Lawrentschuk, Nathan
    LIFE-BASEL, 2021, 11 (06):
  • [37] Irreversible Electroporation for Surgical Renal Masses in Solitary Kidneys: Short-Term Interventional and Functional Outcome
    Diehl, Steffen J.
    Rathmann, Nils
    Kostrzewa, Michael
    Ritter, Manuel
    Smakic, Arman
    Schoenberg, Stefan O.
    Kriegmair, Maximilian C.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 27 (09) : 1407 - 1413
  • [38] Re: Median 5-Year Outcomes of Primary Focal Irreversible Electroporation for Localized Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2023, 209 (06): : 1231 - 1231
  • [39] Robot-Assisted Radical Prostatectomy for the Treatment of Radiation-Resistant Prostate Cancer: Surgical, Oncological and Short-Term Functional Outcomes
    Zugor, Vahudin
    Labanaris, Apostolos P.
    Porres, Daniel
    Heidenreich, Axel
    Witt, Jorn H.
    UROLOGIA INTERNATIONALIS, 2014, 92 (01) : 20 - 26
  • [40] Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy - oncologic and functional outcomes
    Blazevski, A.
    Scheltema, M.
    Yuen, B.
    Cusick, T.
    Masand, N.
    Haynes, A.
    Stricker, P.
    BJU INTERNATIONAL, 2019, 123 : 17 - 18